Table 3 Association of EGFR FISH status and patient characteristics in the EGFR mutation stratum
Characteristics | EGFR mutation | EGFR wild-type | ||||
|---|---|---|---|---|---|---|
FISH + (n = 163) | FISH - (n = 89) | p | FISH+ (n = 62) | FISH - (n = 185) | p | |
Age, years | Â | Â | Â | Â | Â | Â |
  Mean (range) | 56.7 (29–83) | 56.0 (28–80) |  | 57.5 (38–86) | 55.9 (23–80) |  |
Gender | Â | Â | 0.822 | Â | Â | 0.030 |
  Male | 83 (50.9) | 44 (49.4) |  | 35 (56.5) | 132 (71.4) |  |
  Female | 80 (49.1) | 45 (50.6) |  | 27 (43.5) | 53 (28.6) |  |
Smoking status | Â | Â | 0.503 | Â | Â | 0.743 |
  Non-smoker | 120 (73.6) | 62 (69.7) |  | 36 (58.1) | 103 (55.7) |  |
  Smoker | 43 (26.4) | 27 (30.3) |  | 26 (41.9) | 82 (44.3) |  |
Histology | Â | Â | 0.709 | Â | Â | 0.635 |
  Adenocarcinoma | 144 (88.3) | 80 (89.9) |  | 44 (71.0) | 137 (74.1) |  |
  Non-adenocarcinoma | 19 (11.7) | 9 (10.1) |  | 18 (29.0) | 48 (25.9) |  |
Prior platinum | Â | Â | 0.426 | Â | Â | 0.582 |
  Yes | 106 (65.0) | 57 (64.0) |  | 42 (67.7) | 135 (73.0) |  |
  No | 53 (32.5) | 27 (30.3) |  | 18 (29.0) | 42 (22.7) |  |
  Unknown | 4 (2.5) | 5 (5.6) |  | 2 (3.2) | 8 (4.3) |  |
ECOG PS | Â | Â | 0.453 | Â | Â | 0.454 |
  0, 1 | 117 (71.8) | 62 (69.7) |  | 36 (58.1) | 101 (54.6) |  |
  2, 3 | 35 (21.5) | 17 (19.1) |  | 14 (22.6) | 56 (30.3) |  |
  Unknown | 11 (6.7) | 10 (11.2) |  | 12 (19.4) | 28 (15.1) |  |
Disease stage | Â | Â | 0.386 | Â | Â | 0.588 |
  Recurrent | 51 (31.3) | 35 (39.3) |  | 17 (27.4) | 58 (31.4) |  |
  IIIb | 27 (16.6) | 15 (16.9) |  | 15 (24.2) | 34 (18.4) |  |
  IV | 85 (52.1) | 39 (43.8) |  | 30 (48.4) | 93 (50.3) |  |
EGFR-TKI | Â | Â | 0.996 | Â | Â | 0.845 |
  Gefitinib | 119 (73.0) | 65 (73.0) |  | 37 (59.7) | 113 (61.1) |  |
  Erlotinib | 44 (27.0) | 24 (27.0) |  | 25 (40.3) | 72 (38.9) |  |
Line of TKI therapy | Â | Â | 0.515 | Â | Â | 0.344 |
  Fist | 39 (23.9) | 22 (24.7) |  | 11 (17.7) | 32 (17.3) |  |
  Second | 79 (48.5) | 37 (41.6) |  | 32 (51.6) | 78 (42.2) |  |
  Higher | 45 (27.6) | 30 (33.7) |  | 19 (30.6) | 75 (40.5) |  |